Blog
RSS FeedPosted by Michael Wonder on 08 Jul 2016
The bottom line
8 July 2016 - t's hard to put a value on a human life. When you're well, perhaps you don't think ...
Posted by Michael Wonder on 08 Jul 2016
Japan's Eisai weighs legal action in UK cancer drug row
8 July 2016 - Japan's Eisai said on Friday it would consider all options, including possible legal action, to fight delays ...
Posted by Michael Wonder on 08 Jul 2016
Rare Cancers Australia lodges PBAC submission
8 July 2016 - Rare Cancers Australia has lodged a submission for the reimbursement of MSD's Zolinza (vorinistat) for cutaneous T-cell ...
Posted by Michael Wonder on 07 Jul 2016
NICE approves first drug from old Cancer Drugs Fund
7 July 2016 - Dozens of patients with leukaemia will now have an automatic right to the drug bosutinib rather than ...
Posted by Michael Wonder on 07 Jul 2016
Pfizer drug wins U.K. support following overhaul of Cancer Fund
7 July 2016 - Drug costs $58,000 a year before discounts from Pfizer. ...
Posted by Michael Wonder on 07 Jul 2016
Proposal to award sole supply to goserelin acetate (Zoladex) and reference price leuprorelin acetate (Eligard and Lucrin PDS)
7 July 2016 - PHARMAC has entered into a provisional agreement with AstraZeneca. ...
Posted by Michael Wonder on 06 Jul 2016
Charity calls on NICE to reverse Opdivo rejection
6 July 2016 - Kidney Cancer UK is calling on the National Institute for Health and Care Excellence to reverse a ...
Posted by Michael Wonder on 06 Jul 2016
Saskatchewan includes Lemtrada (alemtuzumab) on MS Drugs Program for eligible patients
5 July 2016 - Unique treatment delivered in only two cycles one year apart. ...
Posted by Michael Wonder on 06 Jul 2016
Funding PrEP for HIV prevention
5 July 2016 - Delays by NHS England will cost lives—it’s time to do the right thing. ...
Posted by Michael Wonder on 05 Jul 2016
New Zealand public help improve PHARMAC decision making
6 July 2016 - After listening to what New Zealanders had to say, PHARMAC has changed the way it makes decisions ...
Posted by Michael Wonder on 05 Jul 2016
UK cost agency rejects Bristol's Opdivo for kidney cancer
5 July 2016 - Bristol-Myers Squibb's immunotherapy drug Opdivo is not worth using on the state health service for treating kidney ...
Posted by Michael Wonder on 05 Jul 2016
Unrelated future costs and unrelated future benefits: reflections on NICE Guide to the Methods of Technology Appraisal
3 July 2016 - This editorial considers the vexing issue of ‘unrelated future costs’ (for example, the costs of caring ...
Posted by Michael Wonder on 05 Jul 2016
Factors for consideration
30 June 2016 - The factors for consideration are the framework PHARMAC uses when making funding decisions. ...
Posted by Michael Wonder on 05 Jul 2016
Devices savings to help hospitals manage budgets
5 July 2016 - New data from PHARMAC is predicting DHB hospital spending on surgical and medical devices will fall by ...
Posted by Michael Wonder on 04 Jul 2016
NICE backs Ferring’s Firmagon
4 July 2016 - Men with advanced hormone-dependent prostate cancer and spinal metastases are to gain routine access to Ferring's Firmagon ...